ABCL-121 Immunohistochemistry Expression of MICA, MICB, and Epstein-Barr Virus (EBV) in Lymph Node Biopsy of Patients With De Novo Non-Hodgkin Lymphoma

Abstract

We recently found an increase soluble expression of MICA and MICB in patients with de novo non-Hodgkin lymphoma, negatively affecting the patient's immune response. Now we want to evaluate the expression of MIC-A and MIC-B ligands directly at the site of injury. On the other hand, EBV is the etiological agent most related to the development of cancers, mainly lymphomas, however, in our country there are still no data that evaluate the presence of EBV infection in neoplastic cells of patients with non-Hodgkin lymphoma and its possible relationship with the expression of MICA and MICB. To determine the expression of MICA and MICB in the lymph node and whether Epstein Barr virus infection in patients with de novo non-Hodgkin lymphoma favors the soluble expression of MIC-A and MIC-B. Sections will be obtained from the paraffin-embedded block of the neoplastic lymph node of each patient to determine the presence of EBV by LMP-1 expression, as well as the expression of MIC-A, MIC-B by immunohistochemistry. 30 paraffin blocks from patients diagnosed with non-Hodgkin lymphoma were worked on. Of the 30 blocks analyzed, 16 were DLBCL, 6 FL, 5 mycosis fungoides, 1 MCL, 1 NLTCL, and 1 ALCL. The expression of the LMP-1 protein was found in 57%. All cases of mycosis fungoides were positive for EBV and all cases of follicular lymphoma were negative. In all patients, the staining was positive for the presence of MIC-A as well as for MIC-B. The staining pattern for MIC-A was stronger and more massive than for MIC-B, which could indicate a greater expression of MIC-A than MIC-B in our patients, which is consistent with what was reported in the serology of these patients in our previous work.